KR101660603B1 - 불순물 함량이 낮은 카스포펀진 제제 및 그 제조방법과 용도 - Google Patents

불순물 함량이 낮은 카스포펀진 제제 및 그 제조방법과 용도 Download PDF

Info

Publication number
KR101660603B1
KR101660603B1 KR1020147011189A KR20147011189A KR101660603B1 KR 101660603 B1 KR101660603 B1 KR 101660603B1 KR 1020147011189 A KR1020147011189 A KR 1020147011189A KR 20147011189 A KR20147011189 A KR 20147011189A KR 101660603 B1 KR101660603 B1 KR 101660603B1
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
amino acid
formula
temperature
shelf temperature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020147011189A
Other languages
English (en)
Korean (ko)
Other versions
KR20140069272A (ko
Inventor
윤하이 홍
잉 슈에
리신 사
샤오밍 지
Original Assignee
샹하이 테크웰 바이오파마슈티컬 컴퍼니, 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 샹하이 테크웰 바이오파마슈티컬 컴퍼니, 리미티드 filed Critical 샹하이 테크웰 바이오파마슈티컬 컴퍼니, 리미티드
Publication of KR20140069272A publication Critical patent/KR20140069272A/ko
Application granted granted Critical
Publication of KR101660603B1 publication Critical patent/KR101660603B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020147011189A 2011-09-26 2012-09-25 불순물 함량이 낮은 카스포펀진 제제 및 그 제조방법과 용도 Expired - Fee Related KR101660603B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201110288782.X 2011-09-26
CN201110288782 2011-09-26
CN201110434022.5 2011-12-21
CN201110434022.5A CN102488889B (zh) 2011-09-26 2011-12-21 一种低杂质含量的卡泊芬净制剂及其制备方法和用途
PCT/CN2012/081951 WO2013044788A1 (zh) 2011-09-26 2012-09-25 一种低杂质含量的卡泊芬净制剂及其制备方法和用途

Publications (2)

Publication Number Publication Date
KR20140069272A KR20140069272A (ko) 2014-06-09
KR101660603B1 true KR101660603B1 (ko) 2016-09-27

Family

ID=46180781

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147011189A Expired - Fee Related KR101660603B1 (ko) 2011-09-26 2012-09-25 불순물 함량이 낮은 카스포펀진 제제 및 그 제조방법과 용도

Country Status (7)

Country Link
US (1) US9149502B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR101660603B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (2) CN102488889B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE112012003996T5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2519240B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2014KN00893A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2013044788A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102488886B (zh) * 2011-09-26 2014-03-26 上海天伟生物制药有限公司 一种低杂质含量的卡泊芬净制剂及其制备方法和用途
CN102488889B (zh) 2011-09-26 2014-01-22 上海天伟生物制药有限公司 一种低杂质含量的卡泊芬净制剂及其制备方法和用途
CN103212058A (zh) * 2012-01-18 2013-07-24 江苏恒瑞医药股份有限公司 含有抗真菌药物和乳酸盐缓冲剂的组合物
CN103845725A (zh) * 2012-11-30 2014-06-11 上海医药工业研究院 一种更稳定的卡泊芬净组合物
CN112972378A (zh) * 2014-09-24 2021-06-18 艾瑞朗医疗公司 拟肽大环化合物及其制剂
CN114236018B (zh) * 2022-02-24 2022-08-19 深圳市海滨制药有限公司 一种醋酸卡泊芬净及其异构体的检测方法
EP4364566A1 (en) * 2022-11-04 2024-05-08 B. Braun Melsungen AG Anti-fungal composition

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090054331A1 (en) * 2007-06-01 2009-02-26 Acologix, Inc. High temperature stable peptide formulation
US20100137197A1 (en) * 2007-06-26 2010-06-03 Sachin Mittal Lyophilized anti-fungal composition
CN102153616A (zh) * 2010-12-27 2011-08-17 浙江海正药业股份有限公司 一种环己肽类化合物及其盐的分离纯化方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5952300A (en) * 1996-04-19 1999-09-14 Merck & Co., Inc. Antifungal compositions
AR006598A1 (es) * 1996-04-19 1999-09-08 Merck Sharp & Dohme "composiciones anti-fungosas, su uso en la manufactura de medicamentos y un procedimiento para su preparación"
WO2000051564A1 (en) * 1999-03-03 2000-09-08 Eli Lilly And Company Echinocandin pharmaceutical formulations containing micelle-forming surfactants
US6586574B1 (en) * 1999-08-17 2003-07-01 Nn A/S Stabilization of freeze-dried cake
CN101516387B (zh) * 2006-07-26 2014-06-04 桑多斯股份公司 卡泊芬净制剂
US20090291996A1 (en) * 2008-05-21 2009-11-26 Ferenc Korodi Caspofungin free of caspofungin Co
CN102076707A (zh) * 2008-06-25 2011-05-25 特瓦药厂私人有限公司 无卡泊芬净杂质a的卡泊芬净
US20100256074A1 (en) 2008-06-25 2010-10-07 Chaim Eidelman Processes for preparing high purity aza cyclohexapeptides
CN102219832B (zh) * 2010-04-15 2013-08-21 上海天伟生物制药有限公司 一种氮杂环六肽或其盐的纯化方法
CN102488886B (zh) * 2011-09-26 2014-03-26 上海天伟生物制药有限公司 一种低杂质含量的卡泊芬净制剂及其制备方法和用途
CN102488889B (zh) * 2011-09-26 2014-01-22 上海天伟生物制药有限公司 一种低杂质含量的卡泊芬净制剂及其制备方法和用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090054331A1 (en) * 2007-06-01 2009-02-26 Acologix, Inc. High temperature stable peptide formulation
US20100137197A1 (en) * 2007-06-26 2010-06-03 Sachin Mittal Lyophilized anti-fungal composition
CN102153616A (zh) * 2010-12-27 2011-08-17 浙江海正药业股份有限公司 一种环己肽类化合物及其盐的分离纯化方法

Also Published As

Publication number Publication date
WO2013044788A1 (zh) 2013-04-04
US20140221274A1 (en) 2014-08-07
CN102488889A (zh) 2012-06-13
CN102488889B (zh) 2014-01-22
CN103386117A (zh) 2013-11-13
DE112012003996T5 (de) 2014-08-14
ES2519240R1 (es) 2014-11-12
CN103386117B (zh) 2015-09-30
KR20140069272A (ko) 2014-06-09
US9149502B2 (en) 2015-10-06
IN2014KN00893A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-10-09
ES2519240A2 (es) 2014-11-06
ES2519240B1 (es) 2015-08-19

Similar Documents

Publication Publication Date Title
KR101720396B1 (ko) 불순물 함량이 낮은 카스포펀진 제제 및 그 제조방법과 용도
KR101660603B1 (ko) 불순물 함량이 낮은 카스포펀진 제제 및 그 제조방법과 용도
EP2373293B2 (en) Compositions with reduced dimer formation
RU2607526C2 (ru) Липопептидные композиции и родственные способы
EP2624818B1 (en) Bortezomib formulations stabilised with boric acid
DK2618814T3 (en) Caspofunginsammensætning
AU2008269140A1 (en) Lyophilized anti-fungal composition
KR20150135242A (ko) C1 에스터라제 억제제 결핍과 관련된 장애의 예방 및 치료를 위한 c1-inh 조성물 및 방법
CN102526700A (zh) 一种注射用醋酸奥曲肽冻干组合物及其制备方法
BG106578A (bg) Фармацевтични състави на фибринолитичен агент
CN102670522B (zh) 含有重组人血清白蛋白-人粒细胞集落刺激因子融合蛋白的药物制剂及其制备
CN114159396A (zh) 一种注射用艾司奥美拉唑钠冻干制剂及其制备方法
JP2015078177A (ja) 室温保存用凍結乾燥製剤
CN109517033B (zh) 活性肽、重组载体、重组细胞、抗炎组合物及其制备方法和应用
CN102488887B (zh) 一种含有棘白菌素类抗真菌剂卡泊芬净的药用组合物及其制备方法和用途
CN102614493B (zh) 一种含有棘白菌素类抗真菌剂卡泊芬净的液体药用组合物
CN115590825A (zh) 一种注射用达托霉素及其制备方法
EP3207936B1 (en) Stable peptide composition
CN104043101B (zh) 一种艾替班特注射用组合物及其制备方法和制剂
CN105327355A (zh) 一种肠胃外注射用肽药物的稳定制剂及其制备方法
CN108992413A (zh) 一种培美曲塞二钠冻干粉针剂及其制备方法
EA026064B1 (ru) Твердая фармацевтическая композиция, полученная с помощью предварительной стадии замораживания и стадии лиофилизации
CN117597127A (zh) 稳定的ruc-4制剂
CN116712438A (zh) 注射用氨曲南阿维巴坦钠冻干制剂及其制备方法
RU2006110563A (ru) Фармацевтическая композиция, способ ее получения и терапевтическое применение

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20190916

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20230922

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20230922